Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2021 Financial Results and Business UpdatePRNewsWire • 02/22/22
Rigel PharmaceuticalsA Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety NetSeeking Alpha • 02/01/22
Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune ThrombocytopeniaPRNewsWire • 12/21/21
Rigel Pharmaceuticals: New Omicron Variant Keeps Tavalisse Treatment Prospects AliveSeeking Alpha • 11/30/21
Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
Rigel Announces Conference Call and Webcast to Report Third Quarter 2021 Financial Results and Business UpdatePRNewsWire • 10/26/21
Rigel Pharma: Positive Data Supports Use Of Tavalisse In COVID-19 As Variants Subterfuge VaccinesSeeking Alpha • 09/06/21
Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious DiseasesPRNewsWire • 09/01/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rigel Pharmaceuticals, Inc. - RIGLNewsfile Corp • 08/17/21
Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock OptionsZacks Investment Research • 08/11/21
Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/04/21
Rigel Reports Second Quarter 2021 Financial Results and Provides Business UpdatePRNewsWire • 08/03/21
Earnings Preview: Rigel Pharmaceuticals (RIGL) Q2 Earnings Expected to DeclineZacks Investment Research • 07/27/21
Rigel Announces Conference Call and Webcast to Report Second Quarter 2021 Financial Results and Business UpdatePRNewsWire • 07/27/21